XML 61 R50.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition - Effect on Statements of Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 29, 2019
Mar. 30, 2018
Mar. 29, 2019
Mar. 30, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Revenue $ 3,999,987 $ 3,939,311 $ 8,265,336 $ 7,904,429
Costs and Expenses:        
Cost of services provided 3,639,959 3,563,009 7,434,404 7,085,239
Depreciation and amortization 147,908 152,864 298,629 286,713
Selling and general corporate expenses 88,285 88,444 192,415 180,612
Costs and Expenses 3,877,152 3,804,317 7,769,139 7,552,564
Operating income 122,835 134,994 496,197 351,865
Gain on sale of Healthcare Technologies 1,000 0 (156,309) 0
Interest and Other Financing Costs, net 84,178 92,653 167,155 166,786
Income Before Income Taxes 38,657 42,341 329,042 185,079
Provision (Benefit) for Income Taxes 9,347 14,625 49,054 (135,077)
Net income 29,310 27,716 279,988 320,156
Less: Net income (loss) attributable to noncontrolling interest (43) 147 (49) 303
Net income attributable to Aramark stockholders 29,353 $ 27,569 280,037 $ 319,853
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Revenue (91,583)   (180,090)  
Costs and Expenses:        
Cost of services provided (94,490)   (183,197)  
Depreciation and amortization 4,893   7,899  
Selling and general corporate expenses 0   0  
Costs and Expenses (89,597)   (175,298)  
Operating income (1,986)   (4,792)  
Gain on sale of Healthcare Technologies 0   0  
Interest and Other Financing Costs, net 0   0  
Income Before Income Taxes (1,986)   (4,792)  
Provision (Benefit) for Income Taxes (514)   (1,241)  
Net income (1,472)   (3,551)  
Less: Net income (loss) attributable to noncontrolling interest 0   0  
Net income attributable to Aramark stockholders (1,472)   (3,551)  
Calculated under Revenue Guidance in Effect before Topic 606        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Revenue 3,908,404   8,085,246  
Costs and Expenses:        
Cost of services provided 3,545,469   7,251,207  
Depreciation and amortization 152,801   306,528  
Selling and general corporate expenses 88,285   192,415  
Costs and Expenses 3,787,555   7,593,841  
Operating income 120,849   491,405  
Gain on sale of Healthcare Technologies 1,000   (156,309)  
Interest and Other Financing Costs, net 84,178   167,155  
Income Before Income Taxes 36,671   324,250  
Provision (Benefit) for Income Taxes 8,833   47,813  
Net income 27,838   276,437  
Less: Net income (loss) attributable to noncontrolling interest (43)   (49)  
Net income attributable to Aramark stockholders $ 27,881   $ 276,486